Jowsey J, Riggs B L, Kelly P J, Hoffman D L
J Clin Endocrinol Metab. 1978 Sep;47(3):633-9. doi: 10.1210/jcem-47-3-633.
Calcitonin has been considered of therapeutic value in osteoporosis because of its effects in tissue culture. In the whole animal, however, the predominant result seems to be hypocalcemia, which might be expected to have the opposite effect of stimulating parathyroid hormone secretion and therefore resorption of bone. Indeed, in a short term study of 3- and 4-month duration in osteoporotic women, this was found to be so. A combination of calcium and calcitonin was therefore considered a more promising therapeutic alternative for this disease. Calcium was given to 26 patients, alone or with vitamin D, for a period of 15 months, and the effects on serum and urine calcium and phosphorus and on bone resorption and formation were evaluated. Calcium and vitamin D decreased serum parathyroid hormone levels, reduced bone resorption, and increased urinary calcium. The addition of calcitonin to the calcium and vitamin D did not seem to change these effects. Neither form of treatment resulted in change of bone mass. Calcium, with or without vitamin D supplements, may prevent the development of osteoporosis, but it seems unlikely that calcitonin has any additional desirable effect in the disease.
由于降钙素在组织培养中的作用，它被认为对骨质疏松症具有治疗价值。然而，在整个动物体内，主要的结果似乎是低钙血症，这可能会产生相反的效果，即刺激甲状旁腺激素分泌，从而导致骨吸收。事实上，在一项针对骨质疏松症女性进行的为期3至4个月的短期研究中，情况确实如此。因此，钙和降钙素的组合被认为是治疗这种疾病更有前景的替代方法。给26名患者单独或与维生素D一起服用钙，为期15个月，并评估其对血清和尿钙、磷以及骨吸收和形成的影响。钙和维生素D降低了血清甲状旁腺激素水平，减少了骨吸收，并增加了尿钙。在钙和维生素D中添加降钙素似乎并没有改变这些效果。两种治疗方式均未导致骨量变化。补充或不补充维生素D的钙可能会预防骨质疏松症的发展，但降钙素似乎不太可能对该疾病产生任何额外的有益效果。
